OTSUKA PHARMACEUTICAL CO., LTD.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT03724942
- Locations
- π―π΅
Jisenkai Nanko Psychiatric Institute, Shirakawa, Japan
A Study of Brexpiprazole in Patients With Major Depressive Disorder
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 740
- Registration Number
- NCT03697603
- Locations
- π―π΅
Nanko-kokorono clinic, Fukushima, Japan
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 410
- Registration Number
- NCT03620981
- Locations
- π―π΅
Jisenkai Nanko Psychiatric Institute, Shirakawa, Japan
Phase I Study of OPC-61815
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03510663
- Locations
- π―π΅
Kyusyu Region, Fukuoka, Japan
Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT03342963
- Locations
- π―π΅
Clinic of Kyusyu Region, Fukuoka, Japan
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT03303092
- Locations
- π―π΅
Saitama Medical University Hospital, Iruma, Japan
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03303105
- Locations
- π―π΅
Saitama Medical University Hospital, Iruma, Japan
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 571
- Registration Number
- NCT03303079
- Locations
- π―π΅
Saitama Medical University Hospital, Iruma, Japan
A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT03284177
- Locations
- π―π΅
Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
π―π΅Kawasaki Medical School Hospital, Kurashiki, Japan
π―π΅Akita University Hospital, Akita, Japan
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03255226
Β© Copyright 2024. All Rights Reserved by MedPath